BRPI0910509A2 - composição farmacêutica, anticorpos, uso do anticorpo, polipeptídeos, polipeptídeo de cdr de cadeia pesada, polipeptídeo de cdr de cadeia leve e dna - Google Patents

composição farmacêutica, anticorpos, uso do anticorpo, polipeptídeos, polipeptídeo de cdr de cadeia pesada, polipeptídeo de cdr de cadeia leve e dna

Info

Publication number
BRPI0910509A2
BRPI0910509A2 BRPI0910509A BRPI0910509A BRPI0910509A2 BR PI0910509 A2 BRPI0910509 A2 BR PI0910509A2 BR PI0910509 A BRPI0910509 A BR PI0910509A BR PI0910509 A BRPI0910509 A BR PI0910509A BR PI0910509 A2 BRPI0910509 A2 BR PI0910509A2
Authority
BR
Brazil
Prior art keywords
chain cdr
cdr polypeptide
polypeptides
antibodies
dna
Prior art date
Application number
BRPI0910509A
Other languages
English (en)
Inventor
Fumiyoshi Okano
Masaki Shimizu
Takanori Saito
Takayoshi Ido
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of BRPI0910509A2 publication Critical patent/BRPI0910509A2/pt
Publication of BRPI0910509B1 publication Critical patent/BRPI0910509B1/pt
Publication of BRPI0910509B8 publication Critical patent/BRPI0910509B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0910509A 2008-07-10 2009-07-10 uso do anticorpo, anticorpo e composição farmacêutica BRPI0910509B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2008-1800572008 2008-07-10
JP2008180057 2008-07-10
JP2009-0873792009 2009-03-31
JP2009087379 2009-03-31
PCT/JP2009/062573 WO2010005068A1 (ja) 2008-07-10 2009-07-10 癌の治療及び予防用医薬組成物

Publications (3)

Publication Number Publication Date
BRPI0910509A2 true BRPI0910509A2 (pt) 2015-09-29
BRPI0910509B1 BRPI0910509B1 (pt) 2021-05-04
BRPI0910509B8 BRPI0910509B8 (pt) 2021-05-25

Family

ID=41507178

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910509A BRPI0910509B8 (pt) 2008-07-10 2009-07-10 uso do anticorpo, anticorpo e composição farmacêutica

Country Status (16)

Country Link
US (2) US10611835B2 (pt)
EP (1) EP2305300B1 (pt)
JP (1) JP5573156B2 (pt)
KR (1) KR101669834B1 (pt)
CN (1) CN102089004B (pt)
AU (1) AU2009270181B2 (pt)
BR (1) BRPI0910509B8 (pt)
CA (1) CA2730201C (pt)
DK (1) DK2305300T3 (pt)
ES (1) ES2575430T3 (pt)
HU (1) HUE028589T2 (pt)
MX (1) MX2011000117A (pt)
PL (1) PL2305300T3 (pt)
PT (1) PT2305300E (pt)
RU (1) RU2533460C2 (pt)
WO (1) WO2010005068A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016206457B2 (en) 2015-01-16 2021-11-11 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ROR1
JP6752223B2 (ja) 2015-04-16 2020-09-09 アルダー・バイオファーマシューティカルズ・インコーポレーテッド 羞明を処置、予防、または阻害するための抗ｐａｃａｐ抗体及びそれらの抗原結合性断片の使用
US11129893B2 (en) 2015-04-30 2021-09-28 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
CA3012827A1 (en) * 2016-02-02 2017-08-10 Fred Hutchinson Cancer Research Center Anti-ror1 antibodies and uses thereof
CA3020839A1 (en) * 2016-04-15 2017-10-19 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
US12193994B2 (en) 2017-11-06 2025-01-14 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
CN113365660A (zh) 2019-01-29 2021-09-07 朱诺治疗学股份有限公司 对受体酪氨酸激酶样孤儿受体1(ror1)具特异性的抗体及嵌合抗原受体
CN116514961B (zh) * 2022-08-19 2025-06-20 浙江农林大学 抗犬瘟热病毒犬源单链抗体scFv4-15及其制备方法与应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2014073A (en) * 1935-09-10 Stovepipe
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU640397B2 (en) 1989-08-25 1993-08-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
KR100261941B1 (ko) 1994-07-13 2000-07-15 나가야마 오사무 사람의 인터루킨-8에 대한 재구성 사람항체
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
WO1999006541A1 (fr) * 1997-07-29 1999-02-11 Sumitomo Electric Industries, Ltd. Anticorps du recepteur des cellules pre-b non humaines
AU752730B2 (en) 1998-04-03 2002-09-26 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody
EP1268794A2 (en) 2000-04-07 2003-01-02 Heska Corporation Compositions and methods related to canine igg and canine il-13 receptors
EP1485126A4 (en) 2001-12-21 2007-03-21 Idexx Lab Inc DOG IMMUNOGLOBULIN VARIABLE DOMAINS, DOG ANTIBODIES, AND METHOD FOR THEIR PRODUCTION AND USE
US20040110933A1 (en) 2002-09-13 2004-06-10 Dyax Corporation CD44-binding ligands
WO2004048938A2 (en) 2002-11-26 2004-06-10 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2005000901A2 (en) * 2003-05-09 2005-01-06 Duke University Cd20-specific antibodies and methods of employing same
WO2005083074A1 (ja) 2004-03-01 2005-09-09 Kanazawa University Technology Licensing Organization Ltd. 腫瘍抗原ペプチド
US7858753B2 (en) 2004-03-30 2010-12-28 Glaxo Group Limited Immunoglobulins
JP2008512984A (ja) 2004-05-28 2008-05-01 ダナ−ファーバー キャンサー インスティチュート，インコーポレイテッド 癌の同定、評価、予防および治療のための組成物、キットおよび方法
JP4547197B2 (ja) 2004-06-30 2010-09-22 公正 安元 癌特異的腫瘍抗原
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
US20090041783A1 (en) * 2005-04-28 2009-02-12 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
JP2007053501A (ja) 2005-08-16 2007-03-01 Matsushita Electric Ind Co Ltd 管理装置、ｉｐ電話装置、ｉｐ電話システム及び更新方法
CN101074261A (zh) * 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 Trail受体1和/或trail受体2特异性抗体及其应用
ES2378097T3 (es) * 2006-06-02 2012-04-04 Aveo Pharmaceuticals, Inc. Proteínas de unión al factor de crecimiento de hepatocitos (HGF)
WO2008034076A2 (en) * 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2008034074A2 (en) * 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
WO2008141197A1 (en) 2007-05-10 2008-11-20 Sea Lane Biotechnologies, Llc Chain reaction creating oligomers from repeat units of binding molecules
DK2319533T3 (en) 2008-07-10 2017-07-17 Toray Industries IMMUNITY-INducing Agent and Method of Detecting Cancer
TWI516501B (zh) * 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
LT2530091T (lt) * 2010-01-29 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Anti-dll3 antikūnas
NZ604510A (en) * 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use

Also Published As

Publication number Publication date
HUE028589T2 (en) 2016-12-28
BRPI0910509B1 (pt) 2021-05-04
US20200247888A1 (en) 2020-08-06
EP2305300A4 (en) 2011-11-02
RU2011104709A (ru) 2012-08-20
AU2009270181B2 (en) 2014-05-29
CN102089004A (zh) 2011-06-08
KR101669834B1 (ko) 2016-10-27
PL2305300T3 (pl) 2016-09-30
EP2305300B1 (en) 2016-04-06
AU2009270181A1 (en) 2010-01-14
CA2730201C (en) 2019-02-05
BRPI0910509B8 (pt) 2021-05-25
PT2305300E (pt) 2016-06-16
ES2575430T3 (es) 2016-06-28
JP5573156B2 (ja) 2014-08-20
DK2305300T3 (en) 2016-06-06
US20110129478A1 (en) 2011-06-02
US10611835B2 (en) 2020-04-07
RU2533460C2 (ru) 2014-11-20
JPWO2010005068A1 (ja) 2012-01-05
CN102089004B (zh) 2018-06-01
MX2011000117A (es) 2011-02-25
WO2010005068A1 (ja) 2010-01-14
US11993650B2 (en) 2024-05-28
CA2730201A1 (en) 2010-01-14
KR20110039423A (ko) 2011-04-18
EP2305300A1 (en) 2011-04-06

Similar Documents

Publication Publication Date Title
HUS2300026I1 (hu) Anti-CTLA-4 ellenanyag készítmények
BRPI0910509A2 (pt) composição farmacêutica, anticorpos, uso do anticorpo, polipeptídeos, polipeptídeo de cdr de cadeia pesada, polipeptídeo de cdr de cadeia leve e dna
BRPI1005322A2 (pt) anticorpo, composição farmacêutica e uso de pelo menos um anticorpo
BRPI0924177A2 (pt) Polipeptídeos, seu método de preparação, sua composição, sequência de nucleotídeo e uso
BRPI0820543A2 (pt) Anticorpo monoclonal capaz de ligar a anexelekto, e uso do mesmo
BRPI0812400A2 (pt) Unidade, hibridoma, composição farmacêutica, método para identificar uma unidade, anticorpo isolado a uma unidade de ligação de antígeno do mesmo, molécula peptídica, e, uso da unidade.
BRPI0818437A2 (pt) Anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menosum dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma
CU23869B1 (es) Anticuerpos anti-esclerostina y proteínas funcionales
BRPI0905076A2 (pt) Polipeptídeo, anticorpo, região variável, cadeia pesada ou cadeia leve, gene, vetor, célula hospedeira, método para produzir o referido polipeptídeo, e composição farmacêutica compreendendo o mesmo
BRPI0918947A2 (pt) proteína de fusão de anticorpo
BRPI0821447A2 (pt) Anticorpo de alvejamento engenheirado, composição farmacêutica, hibridoma, ensaio com base em anticorpo, polipeptídeo isolado, e, método para ligação homogênea
PT2162467E (pt) Polipéptidos, domínios variáveis de anticorpo e antagonistas
BRPI0906478A2 (pt) anticorpo anti-nr10 e uso do mesmo
IL205705A (en) Anti-influenza antibodies, compositions comprising the same and uses thereof
IL201399A0 (en) Polypeptides, antibody variable domains and antagonists
BRPI0819299A2 (pt) Uso de composição, e, composição contendo proteína
IL219653A0 (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
HUE038501T2 (hu) Antitest készítmények
BRPI0923199A2 (pt) métodos e composições para detecção de anticorpos com fixação de complemento.
CL2014000400A1 (es) Proteina de union al antigeno especifica para el heterodimero alfa4beta7; y composicion que la comprende (div.sol.n°2306-11).
PT3620171T (pt) Anticorpos anti-gm-csf e suas utilizações
BRPI0819210A2 (pt) Anticorpos de proteína g anti-rsv
BRPI0811637A2 (pt) Proteínas de fusão da imunoglobina
BRPI0908097A2 (pt) uso de pelo menos um composto, peptídeo, e, formulação farmacêutica.
NO20083891L (no) Anti-5T4 antistoffer og anvendelser derav

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/07/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/07/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF